Business Wire

CA-QUANERGY-SYSTEMS

26.9.2018 16:11:02 CEST | Business Wire | Press release

Share
Quanergy Announces Availability of Power Over Ethernet for M8 LiDAR Sensor

Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, today announced the availability of its M8 LiDAR sensor with Power over Ethernet (PoE+). This new connector interface, designed specifically for the security market, allows the sensor to be easily installed and integrated with new or existing security systems, without costly custom wiring to power the LiDAR sensor.

Surveillance systems leverage PoE to transmit power and data across the sensor and system. The IEEE 802.3at (PoE+) specification provides more power to PoE-powered devices and allows for a broader range of devices to be easily integrated into a network via standard Ethernet cable. The release of the M8 with PoE+ allows for a simpler, more flexible installation of LiDAR-based security systems. Its plug-and-play usability permits customers to make use of their existing security infrastructure when upgrading to a LiDAR-based security solution, leading to significant savings in implementation cost and time.

The M8 sensor’s long range and 360 degree field of view enables systems to detect and track potential intruders before they physically breach a perimeter. The M8 PoE+ provides a signifcantly smaller overall footprint than other PoE+ sensors and radars. Unlike traditional security camera technology, the M8 operates successfully in challenging weather environments as well as in the dark. Paired with Quanergy’s proprietary LiDAR perception software, QORTEX for Security™, the M8 can be used as a standalone solution, or as an integrated component of a larger security system.

“We built the M8 with Power over Ethernet to enable our security customers to implement a LiDAR-based security system as easily as they would a camera-based surveillance system,” said Dr. Louay Eldada, CEO of Quanergy. “Our LiDAR sensors lead the industry in price, performance, and reliability. With PoE+, our customers can easily harness the power of LiDAR to ensure the highest level of security and awareness around vulnerable perimeters, protecting critical infrastructure such as airports, national borders, subways, power plants, oil fields and prisons.”

In addition to offering its technology as a standalone security solution, Quanergy deploys its technology in partnership with public safety and security technology firms (system integrators or SI) such as Vision Logic, many of whom are already using Power over Ethernet to connect other surveillance tools, such as IP cameras. This new availability allows SIs to flexibly incorporate Quanergy’s LiDAR technology into existing security systems, reducing installation time and costs.

“Integrating LiDAR technology into our video surveillance and facial recognition systems enables us to offer an unparalleled level of security and awareness to our customers,” said John Walsh, co-founder of Vision Logic. Graham Conran, co-founder and CEO of Vision Logic added “With Power over Ethernet, we can more easily incorporate Quanergy’s industry leading LiDAR sensors into our public safety and security platforms, tailoring our solutions to each of our customers’ needs.”

The M8 with PoE+ will be on display at two leading security industry events. Quanergy will be exhibiting at GSX in Las Vegas, September 25-27, in booth #2885. At Security Essen in Germany, September 26-28, the sensor will be in both the Milestone Systems and Genetec booths in Hall 5. Genetec will be in booth #5G30 and Miletsone will be in booth #5F10. General availability of the M8 sensor with PoE+ is November 2018.

About Quanergy Systems, Inc.

Quanergy Systems, Inc. was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers smart sensing solutions. It is the leading provider of LiDAR sensors and perception software for real-time capture and processing of 3D spatial data and object detection, identification, classification and tracking. Its sensors are disruptive in price, performance, reliability, size, weight and power. Its solutions are applicable in numerous sectors including transportation, security, industrial automation, 3D mapping, mining, agriculture, drones, robotics, smart spaces and 3D-aware smart devices for improved safety, efficiency and quality of life. For more information, visit www.quanergy.com .

Contact:

Quanergy Systems, Inc. Ann Gargiulo, +1-408-245-9500 Director of Marketing Communications media@quanergy.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye